Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
1.300
+0.022 (1.70%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Lyra Therapeutics Revenue
Lyra Therapeutics had revenue of $25.00K in the quarter ending September 30, 2025, a decrease of -87.18%. This brings the company's revenue in the last twelve months to $600.00K, down -59.21% year-over-year. In the year 2024, Lyra Therapeutics had annual revenue of $1.53M, down -1.54%.
Revenue (ttm)
$600.00K
Revenue Growth
-59.21%
P/S Ratio
3.79
Revenue / Employee
$20,000
Employees
30
Market Cap
2.31M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLYRA News
- 2 months ago - Lyra Therapeutics Provides Corporate Update - GlobeNewsWire
- 4 months ago - Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study - GlobeNewsWire
- 7 months ago - Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - GlobeNewsWire
- 9 months ago - Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst - Seeking Alpha
- 10 months ago - Why Is Lyra Therapeutics Stock Surging Over 400% On Monday? - Benzinga
- 10 months ago - Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewsWire